Novo, Mylan Jockey Over Trial Timing in Wegovy Patent Dispute

Novo Nordisk A/S is pushing for a 2027 trial date—at the earliest—in its suit against Viatris Inc.'s Mylan unit over “second-generation” Wegovy patents, as Mylan argues a long wait prolongs uncertainty over its generic’s launch.

Moving the trial to 2027 or later would risk fading witness memories, increase costs, and narrow the window for completing any appeal before the 2031 expiration of the core semaglutide patent at issue in the case, Mylan said in a Feb. 13 letter in the US District Court for the District of Delaware. A redacted version was filed Feb. 20.

Novo’s Feb. 20 response said ...